

## Matt Regan – Education and Professional Qualifications



Year	Institution	Degree
2002	University of Ireland, Galway, Ireland	Executive MBA with Distinction
1993	Institute of Technology, Athlone, Ireland	Bachelor of Science (in Polymer Science) with First Class Honours

Matt is currently CEO and a member of the Board of Directors at Micros Pharmaceuticals. In this role, he played a leading part in spinning out and building an innovative biotechnology company focused on dermatology, oncology, and antimicrobial resistance. His core responsibilities included establishing operational infrastructure, defining the strategic scientific direction, and developing a sustainable financing strategy—all with the aim of achieving an IPO by 2027.

Previously, Matt held senior leadership and executive roles at Novo Nordisk and AbbVie. There, he was responsible for high-revenue regions, consistently achieved significant sales growth, and oversaw groundbreaking product launches such as Ozempic in Europe and Humira in the United Kingdom.

As a values-driven leader, Matt places particular emphasis on innovation, talent development, and building agile, purpose-driven organisations. In addition to his strong commercial and strategic expertise, he brings extensive investor-side experience, especially through successful fundraising, leading spin-offs, and managing high-risk transformation initiatives. His global perspective, technical competence, and determination to challenge established structures position him as a valuable asset for boards of directors and as a strategic adviser in the life sciences sector.

### Key competences:

- International management experience in the areas of biotech, pharmaceuticals and medical technology across seven countries
- In-depth expertise in commercialization, market access and product lifecycle management
- Proven success in strategic corporate development, capital raising and company spin-off
- Significant expertise in the successful launch of market-leading products in Europe and growth markets
- Experience in managing large income statements and complex corporate structures (sales of \$3 billion+, 3,500+ employees)
- Confident in dealing with investors, developing value-added strategies and preparing for IPOs
- Extensive operational expertise in manufacturing, human resource management, supply chain control, and research and development